
Claims:

150LZTED?

- 1. A mutant cytomegalovirus pp65 protein which lacks protein kinase activity, wherein said cytomegalovirus pp65 protein elicits a CTL response against cells infected with cytomegalovirus.
- 2. An isolated cytomegalovirus pp65 protein of claim 1, which contains the K436N mutation.
 - 3. A DNA encoding a cytomegalovirus pp65 protein of claim 1.
 - 4. A DNA encoding a cytomegalovirus pp65 protein of claim 2.
 - 5. A DNA which comprises pcDNAintpp65mII.
 - 6. A vaccine composition which comprises a cytomegalovirus pp65 protein of claim 1 and a pharmaceutically acceptable carrier.
 - 7. A vaccine composition which comprises a cytomegalovirus pp65 protein of claim 2 and a pharmaceutically acceptable carrier.
 - 8. A cellular vaccine composition which comprises antigen presenting cells that have been treated *in vitro* so as to present epitopes of a cytomegalovirus pp65 protein of claim 1 and a pharmaceutically acceptable carrier.
 - 9. A cellular vaccine composition which comprises antigen presenting cells that have been treated *in vitro* so as to present epitopes of a cytomegalovirus pp65 protein of claim 2 and a pharmaceutically acceptable carrier.

- 10. A DNA vaccine composition which comprises a DNA of claim 3 and a pharmaceutically acceptable carrier.
- 11. A DNA vaccine composition which comprises a DNA of claim 4 and a pharmaceutically acceptable carrier.
- 12. A DNA vaccine composition which comprises a DNA of claim 5 and a pharmaceutically acceptable carrier.
- 13. A DNA vaccine composition of claim 12 which further comprises an adjuvant.
- 14. A eukaryotic virus vector which comprises a DNA of claim 3.
- 15. A eukaryotid virus vector which comprises a DNA of claim 4.
- 16. A eukaryotic virus vector which comprises a DNA of claim 5.
- 17. A recombinant live virus vaccine which comprises a DNA of claim 3.
- 18. A recombinant live virus vaccine which comprises a DNA of claim 4.
- 19. A recombinant live virus vaccine which comprises a DNA of claim 5.
- 20. A method of enhancing immunity to cytomegalovirus which comprises administering a vaccine composition of any of claims 6-13 or 17-19.



22. A diagnostic reasent for detecting the presence of active versus quiescent atomegalovirus infections which comprises pp65mII transfected target antigen presenting cells.

addar/